Ramot

What Ramot does

Ramot is the official technology transfer company (TTO) of Tel Aviv University, established to identify, protect, and commercialize inventions arising from the university's research base. Founded in 1973 and headquartered at the Tel Aviv University campus in Tel Aviv, Israel, Ramot operates as a non-profit entity wholly owned by the university and manages a portfolio of 236 technologies spanning 13 fields of expertise — therapeutics, diagnostics, agtech & foodtech, materials & nanotech, climate & energy, medical devices & digital health, quantum computing, synthetic biology, security & defense, electronics & optics, ICT & AI, mechanical systems & robotics, and research tools — supported by 159 capability labs and approximately 1,315 researchers.

The organization generates revenue through technology licensing (upfront fees, milestone payments, and royalties), research collaboration agreements with industry partners, and equity participation in spin-off companies built around TAU intellectual property. Notable technologies under commercialization include a noncoding RNA-based pancreatic cancer diagnostic platform, mRNA Boolean circuit cancer therapy technology, a computational gene expression platform with 60+ rules for protein yield and viral titer optimization, transformer-based quantum error correction decoders, CLARIFY eye imaging for needle-free blood counts, and Aramchol-related metastatic brain cancer research. Ramot also offers industrial research services — High Throughput Genomics and Computational Modeling of Gene Expression — providing bioinformatics, RNA-seq, ribosome profiling, and biophysical modeling to industry clients.

Ramot serves enterprise clients, primarily pharmaceutical, biotech, and technology companies, through direct licensing, sponsored research collaborations, and spin-off formation. Established corporate partners include Tata, Qualcomm, Microsoft, Pfizer, Samsung, Merck, Pitango, Shire, Wipro, SanDisk, and Baxter. Distribution channels are enterprise-direct via negotiated licensing agreements with global reach across Israel, North America, and Asia Pacific. The leadership team is led by CEO Dr. Ronen Kreizman and Chairman Haggai Itkin, with domain-specialized VPs covering intellectual property and business development across exact sciences, high-tech and engineering, and life sciences.

Name

Ramot

Legal name

Ramot at Tel Aviv University

Website

https://ramot.org

Company type

Private

Founded year

1973

Operating status

Operating

Headcount range

11–50 employees

Short description

Ramot is the official technology transfer company of Tel Aviv University, managing 236+ technologies across 13 fields and commercializing them through licensing, research collaborations, and spin-off formation for enterprise partners globally.

Ownership category

akta.pro rank

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Technology Licensing: Ramot licenses Tel Aviv University technologies to industry partners, generating licensing fees and royalties from commercialized innovations.
2. Research Collaborations: Facilitates and participates in research collaboration agreements between TAU researchers and pharmaceutical/biotech companies.
3. Startup Support and Equity: Supports creation of spin-off companies from university research, potentially holding equity stakes in these ventures.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Ramot is the official technology transfer company of Tel Aviv University, identifying, nurturing, and transforming TAU inventions into commercial products. It provides intellectual property protection, technology licensing, research collaboration agreements with industry partners, and spin-off company formation support across 13 technology domains including therapeutics, diagnostics, agtech, quantum computing, AI, and medical devices.

Product overview

Ramot is the technology transfer company of Tel Aviv University, operating as a technology licensing and commercialization organization rather than a traditional product company. Its portfolio consists of research services and technologies available for licensing from TAU researchers. The main services include High Throughput Genomics and Computational Modeling of Gene Expression, which are laboratory and computational services offered to industry partners. Additionally, Ramot manages a portfolio of 236 technologies across fields including Therapeutics, Diagnostics, Agtech & Foodtech, Materials & Nanotech, Climate & Energy, Medical Device & Digital Health, Quantum Computing, Synthetic Biology, Security & Defence, Electronics & Optics, ICT & AI, Mechanical Systems & Robotics, and Research Tools. These technologies are available for licensing or commercialization through industry partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

• High Throughput Genomics Service A comprehensive genomics analysis service that combines high-throughput methods and bioinformatics to analyze gene regulators such as microRNAs, reaching a global systems perspective on disease development mechanisms. Includes mutation/variant calling, microRNA target identification, whole exome sequencing, and statistical analysis of TCGA data. Targeted at pharma, biotech, and academic collaborators.
• Computational Modeling of Gene Expression Service A computational biology service focused on developing predictive models for analyzing and simulating different stages of gene expression. Includes engineering gene expression for biotechnological objectives, deciphering the gene expression code, and analyzing gene expression in diseases. Provides ribosome profiling analysis, RNA-seq data analysis, and biophysical modeling of intracellular phenomena. Targeted at biotech and pharma partners.
• Computational Platform for Gene Expression Enhancement A computational platform for enhancing gene expression to increase protein yield and viral titer. Applies over 60 rules affecting gene/protein expression for controlling protein expression levels, stability, and folding; designing genes tailored to host organisms; attenuating viruses for vaccines; and discovering non-coding mutations in disease. Available for licensing to biotech and pharmaceutical companies.
• Noncoding RNA-Based Pancreatic Cancer Diagnostic Platform A blood test RNA-based diagnostic platform leveraging non-coding RNAs (ncRNAs) as biomarkers for early-stage pancreatic ductal adenocarcinoma (PDAC) detection. Uses next-generation sequencing, advanced bioinformatics, and machine learning algorithms to identify unique RNA signatures associated with PDAC. Available for licensing to diagnostics companies.
• mRNA Boolean Circuit Cancer Therapy Technology Next-generation mRNA therapy technology that targets cancer cells via Boolean circuits based on mRNA molecules. Uses logic gates opened by cancerous mRNA with toehold switches designed through a computational pipeline to target silent mutations, splicing mutations, and non-silent mutations specific to cancer cells. Available for licensing to pharma and biotech companies.
• Gene Expression for Crop Productivity Platform A platform for enhancing crop productivity by optimizing gene expression in plants using proprietary computational tools and genome base editing capabilities. Includes mRNA translation optimization, computational algorithms for identifying ribosomal bottlenecks, and genome editing for creating yield-impacting variations in crops. Available for licensing to agtech companies.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature1 record

Partnerships

Ten partnerships are on record, tiered core and minor.

• Galmed PharmaceuticalscoreStrategic or Co-development Partner · 14 April 2026Research collaboration agreement to evaluate Galmed's SCD1 inhibitor Aramchol as targeted therapy for metastatic brain cancers. The partnership combines TAU's genomic expertise (Ben-David Lab) with 3D preclinical modeling capabilities (Satchi-Fainaro Lab) to validate Aramchol's efficacy in p53-deficient brain metastases.
• Quantum Transportation Ltd.coreOEM/ Whitelabel/ Licensing Partner · 14 January 2026Quantum Transportation holds an exclusive sub-license from Ramot for an innovative pending patent application in quantum error correction for rail technologies. Rail Vision acquired 51% majority stake in Quantum Transportation and extended a convertible loan facility of up to $700,000.
• DiagnosTear Technologies Inc.minorStrategic or Co-development Partner · 17 December 2025DiagnosTear signed a non-binding term sheet to exclusively license the CLARIFY technology from Sheba Medical Center and Tel Aviv University. CLARIFY is an eye imaging platform designed for blood counts without traditional blood draws.
• Viewbix Inc.coreTechnology or Integration · 15 December 2025Viewbix is acquiring Quantum X Labs Ltd., with Milestone 1 of the Transformer-Based Quantum Decoder program fulfilled requirements tied to an IP license from Ramot. The milestone secured rights to a machine-learning-powered QEC decoder.
• TatacoreOthersCorporate partner displayed in business partners section of Ramot website, indicating ongoing commercial relationship.
• QualcommcoreOthersCorporate partner displayed in business partners section of Ramot website, indicating ongoing commercial relationship.
• MicrosoftcoreOthersCorporate partner displayed in business partners section of Ramot website, indicating ongoing commercial relationship.
• PfizercoreOthersCorporate partner displayed in business partners section of Ramot website, indicating ongoing commercial relationship in life sciences.
• SamsungcoreOthersCorporate partner displayed in business partners section of Ramot website, indicating ongoing commercial relationship.
• MerckcoreOthersCorporate partner displayed in business partners section of Ramot website, indicating ongoing commercial relationship in pharmaceuticals/life sciences.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cambridge Enterprise: Cambridge Enterprise is the TTO of the University of Cambridge. It is a leading European peer with a comparable model — licensing IP, running consulting services, and creating spin-outs — and serves as a benchmark for international TTOs that compete for the same global pharma and tech licensing partners.
• Yissum Technology Transfer: Yissum is the TTO of the Hebrew University of Jerusalem and one of the most prolific university TTOs globally. It is a direct peer operating the same licensing and spin-out model in the same Israeli ecosystem, with comparable life-sciences and chemistry strengths.
• Oxford University Innovation (OUI): OUI is the TTO of the University of Oxford and operates a model near-identical to Ramot's: IP protection, licensing, consulting services, and spin-out formation. Comparable in breadth (life sciences, deep tech, AI) and in multinational partner base.
• BIRAD - Bar-Ilan Research and Development Company: BIRAD is the TTO of Bar-Ilan University, performing the same licensing, sponsored research, and spin-off formation function as Ramot within the Israeli university system.
• Yeda Research and Development Company: Yeda is the commercial arm and TTO of the Weizmann Institute of Science in Israel. It is the closest direct peer to Ramot: same model (university TTO), same geography, and competing for the same Israeli deep-tech and pharma multinational partner attention.
• Technion Technology Transfer (T3): T3 is the TTO of the Technion – Israel Institute of Technology. Like Ramot, it licenses inventions, facilitates research collaborations, and creates spin-offs in engineering, life sciences, and computer science, and competes for similar corporate licensing partners.

Others

• Tech Transfer Weeks / AUTM community members: AUTM is the global industry association for technology transfer professionals. While not a single peer, Ramot operates within the AUTM peer set of university TTOs, which collectively sets licensing norms, royalty benchmarks, and best practices that directly affect Ramot's deal economics.
• Pitango Venture Capital: Pitango is Israel's largest venture capital firm and a listed partner of Ramot. It is an adjacent ecosystem participant — not a TTO — but it co-invests in TAU spin-offs and competes for the same Israeli deep-tech deal flow that Ramot helps originate.

Broad incumbents

• MIT Technology Licensing Office (TLO): MIT TLO is the technology transfer office of MIT, one of the largest and most prolific university licensing organizations globally. It is a broader incumbent peer with a far larger portfolio, but operates the same licensing and equity-in-spinoffs model as Ramot.
• Stanford Office of Technology Licensing (OTL): Stanford OTL licenses Stanford University inventions and manages equity in spin-offs using a similar royalty-and-equity model to Ramot. It is a global benchmark incumbent for university TTO economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ramot-tel-aviv-university-tech-transfer-arm

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ramot